Physician profile
Samantha Ann Sharp
NPI 1598491409
$2,536.09
in general payments reported to CMS, 2019-2025
25 companies · $750 in 2025
The $750 reported for 2025 was more than what 82% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $518 · 2023: $397 · 2024: $872 · 2025: $750.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,019.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,018.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $637.80 | 2022-2025 | |
| Nalu Medical, INC. | $347.97 | 2022 | |
| Abbott Laboratories | $241.22 | 2024 | Freestyle Libre 3 |
| Lilly USA, LLC | $232.23 | 2022-2025 | Taltz, Mounjaro, Zepbound |
| Astrazeneca Pharmaceuticals LP | $211.20 | 2024-2025 | Airsupra, Breztri |
| Xeris Pharmaceuticals, INC. | $102.98 | 2025 | Recorlev |
| Novo Nordisk INC | $80.42 | 2024 | Rybelsus, Ozempic |
| Sanofi-Aventis U.S. LLC | $74.28 | 2025 | |
| Glaxosmithkline, LLC. | $64.33 | 2024-2025 | Trelegy Ellipta |
| Stryker Corporation | $62.67 | 2025 | Mako |
| Biohaven Pharmaceutical Holding Company LTD. | $60.91 | 2022 | |
| Collegium Pharmaceutical, INC. | $45.36 | 2022-2023 | Belbuca |
| Amgen INC. | $44.93 | 2022-2025 | Otezla, Repatha |
| Indivior INC. | $43.17 | 2023 | Sublocade |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $42.88 | 2025 | Caplyta |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $40.24 | 2024 | Veozah |
| Exact Sciences Corporation | $40.20 | 2024-2025 | Cologuard Collection Kit |
| Boston Scientific Corporation | $33.30 | 2024-2025 | Axonics |
| Phadia US INC. | $22.71 | 2024 | Immunocap |
| Azurity Pharmaceuticals, INC. | $20.60 | 2024 | Horizant |
| Pfizer INC. | $18.82 | 2023 | |
| Scilex Pharmaceuticals INC. | $18.58 | 2023 | Ztlido |
| Vertos Medical, INC. | $16.82 | 2022 | |
| Merck Sharp & Dohme LLC | $16.52 | 2025 | Capvaxive |
| Axsome Therapeutics, INC. | $15.95 | 2025 | Auvelity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samantha Sharp listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.